NZ507887A
(en)
*
|
1998-05-19 |
2002-12-20 |
Avidex Ltd |
Soluble T cell receptor
|
EP1118661A1
(en)
*
|
2000-01-13 |
2001-07-25 |
Het Nederlands Kanker Instituut |
T cell receptor libraries
|
EP1287363A2
(en)
*
|
2000-05-25 |
2003-03-05 |
Sunol Molecular Corporation |
Modulation of t-cell receptor interactions
|
ATE290020T1
(de)
*
|
2001-08-31 |
2005-03-15 |
Avidex Ltd |
Löslicher t zell rezeptor
|
EP1435776A4
(en)
|
2001-09-24 |
2006-01-25 |
Univ Pittsburgh |
VACCINE AGAINST CANCER AND DIAGNOSTIC PROCEDURE AND REAGENTS
|
US7794693B2
(en)
|
2002-03-01 |
2010-09-14 |
Bracco International B.V. |
Targeting vector-phospholipid conjugates
|
WO2004065621A1
(en)
|
2002-03-01 |
2004-08-05 |
Dyax Corp. |
Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
|
US7261876B2
(en)
|
2002-03-01 |
2007-08-28 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
US8623822B2
(en)
|
2002-03-01 |
2014-01-07 |
Bracco Suisse Sa |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
CA2477935C
(en)
*
|
2002-03-01 |
2015-01-06 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
US7211240B2
(en)
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
US7547517B2
(en)
|
2002-09-27 |
2009-06-16 |
Ludwig Institute For Cancer Research |
MAGE-C2 antigenic peptides and uses thereof
|
US7569664B2
(en)
*
|
2002-10-09 |
2009-08-04 |
Immunocore Limited |
Single chain recombinant T cell receptors
|
CA2505558C
(en)
|
2002-11-09 |
2013-07-02 |
Avidex Limited |
T cell receptor display
|
GB0227351D0
(en)
*
|
2002-11-22 |
2002-12-31 |
Isis Innovation |
Soluble T-cell receptors
|
EP1567553A2
(en)
*
|
2002-12-03 |
2005-08-31 |
Avidex Ltd. |
Complexes of receptors
|
GB0304068D0
(en)
*
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
EP2343083B1
(en)
|
2003-06-27 |
2014-01-15 |
International Institute of Cancer Immunology, Inc. |
Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
|
EP1691661B1
(en)
*
|
2003-11-10 |
2014-01-08 |
Altor BioScience Corporation |
Soluble tcr molecules and methods of use
|
US9090673B2
(en)
*
|
2003-12-12 |
2015-07-28 |
City Of Hope |
Synthetic conjugate of CpG DNA and T-help/CTL peptide
|
US20060014941A1
(en)
*
|
2003-12-22 |
2006-01-19 |
University Of Tennessee Research Foundation, Inc. |
Isolated T lymphocyte receptors specific for human autoantigens complexed with human MHC molecules and methods of making and using same
|
GB0411125D0
(en)
*
|
2004-05-19 |
2004-06-23 |
Avidex Ltd |
Method of improving T-cell receptors
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
GB0427585D0
(en)
*
|
2004-12-16 |
2005-01-19 |
Avidex Ltd |
Assay
|
CN103059128B
(zh)
*
|
2005-04-01 |
2016-01-20 |
英美偌科有限公司 |
高亲和力hiv t细胞受体
|
EP2277918B1
(en)
|
2005-05-13 |
2012-11-14 |
Oxford BioMedica (UK) Limited |
Mhc class I and II peptide antigens derived from tumour antigen 5t4
|
GB0510627D0
(en)
|
2005-05-25 |
2005-06-29 |
Avidex Ltd |
Polypeptides
|
EP1937723B1
(en)
*
|
2005-08-31 |
2013-11-13 |
Invion Limited |
Modified chaperonin 10
|
EP1982176A1
(en)
*
|
2006-01-30 |
2008-10-22 |
Dako Denmark A/S |
High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
|
WO2007117588A2
(en)
*
|
2006-04-05 |
2007-10-18 |
The General Hospital Corporation |
Soluble virus-specific t-cell receptor compositions
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
JP5484041B2
(ja)
*
|
2007-02-23 |
2014-05-07 |
学校法人関西学院 |
蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
|
AU2013206501B2
(en)
*
|
2007-03-05 |
2016-05-19 |
International Institute Of Cancer Immunology, Inc. |
Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene and use of them
|
US10093977B2
(en)
|
2007-03-05 |
2018-10-09 |
International Institute Of Cancer Immunology, Inc. |
Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
|
WO2008116468A2
(en)
|
2007-03-26 |
2008-10-02 |
Dako Denmark A/S |
Mhc peptide complexes and uses thereof in infectious diseases
|
KR100877480B1
(ko)
*
|
2007-06-08 |
2009-01-07 |
왕성호 |
숫자 기억 게임 방법
|
EP2167537A2
(en)
|
2007-07-03 |
2010-03-31 |
Dako Denmark A/S |
Compiled methods for analysing and sorting samples
|
US10611818B2
(en)
|
2007-09-27 |
2020-04-07 |
Agilent Technologies, Inc. |
MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
|
DK2254592T3
(da)
|
2008-02-28 |
2019-09-09 |
Dako Denmark As |
MHC-multimerer til Borrelia-diagnostik og sygdom
|
US10722562B2
(en)
|
2008-07-23 |
2020-07-28 |
Immudex Aps |
Combinatorial analysis and repair
|
WO2010011994A2
(en)
|
2008-07-25 |
2010-01-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polypeptides and uses thereof
|
GB0817244D0
(en)
|
2008-09-20 |
2008-10-29 |
Univ Cardiff |
Use of a protein kinase inhibitor to detect immune cells, such as T cells
|
US11992518B2
(en)
|
2008-10-02 |
2024-05-28 |
Agilent Technologies, Inc. |
Molecular vaccines for infectious disease
|
WO2010037402A1
(en)
|
2008-10-02 |
2010-04-08 |
Dako Denmark A/S |
Molecular vaccines for infectious disease
|
GB0908613D0
(en)
*
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
JP2012531428A
(ja)
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
|
GB0911566D0
(en)
|
2009-07-03 |
2009-08-12 |
Immunocore Ltd |
T cell receptors
|
US10464987B2
(en)
|
2009-10-06 |
2019-11-05 |
Abbvie Inc. |
Human single-chain T cell receptors
|
GB201002730D0
(en)
*
|
2010-02-18 |
2010-04-07 |
Uni I Oslo |
Product
|
US20120258871A1
(en)
|
2011-04-08 |
2012-10-11 |
Prognosys Biosciences, Inc. |
Peptide constructs and assay systems
|
KR20140039318A
(ko)
|
2011-06-28 |
2014-04-01 |
인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 |
펩티드 암 항원 특이적 t 세포의 리셉터 유전자
|
CA2868439C
(en)
|
2012-03-28 |
2023-09-26 |
Umc Utrecht Holding B.V. |
Combinatorial gamma 9 delta 2 t cell receptor chain exchange
|
NZ704157A
(en)
|
2012-07-27 |
2018-08-31 |
Univ Illinois |
Engineering t-cell receptors
|
EP3718556A3
(en)
|
2012-08-31 |
2020-12-30 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
AU2013312529A1
(en)
|
2012-09-05 |
2015-04-16 |
The University Of Birmingham |
Target peptides for colorectal cancer therapy and diagnostics
|
US20160000893A1
(en)
|
2012-12-13 |
2016-01-07 |
University Of Virginia Patent Foundation |
Target peptides for ovarian cancer therapy and diagnostics
|
GB201223172D0
(en)
|
2012-12-21 |
2013-02-06 |
Immunocore Ltd |
Method
|
CN105358984B
(zh)
*
|
2013-03-15 |
2020-02-18 |
普罗格诺西斯生物科学公司 |
用于检测肽/mhc/tcr结合的方法
|
CN105873945B
(zh)
|
2013-11-22 |
2020-07-17 |
伊利诺伊州大学理事会 |
工程化的高亲和力人类t细胞受体
|
US10370427B2
(en)
|
2013-12-19 |
2019-08-06 |
Friedrich-Alexander Universität Erlangen-Nürnberg |
Influenza-specific T-cell receptor and its uses in the detection, prevention and/or treatment of influenza
|
ES2740930T3
(es)
|
2014-03-14 |
2020-02-07 |
Immunocore Ltd |
Bibliotecas de TCR
|
US10654908B2
(en)
|
2014-04-15 |
2020-05-19 |
University Of Virginia Patent Foundation |
Isolated T cell receptors and methods of use therefor
|
GB201409558D0
(en)
*
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
CN106279404A
(zh)
*
|
2015-05-20 |
2017-01-04 |
广州市香雪制药股份有限公司 |
一种可溶且稳定的异质二聚tcr
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
GB201514875D0
(en)
*
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
KR20180043800A
(ko)
|
2015-09-09 |
2018-04-30 |
이뮨 디자인 코포레이션 |
Ny-eso-1 특이적 tcrs 및 그의 사용 방법
|
GB201516277D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR libraries
|
GB201516265D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516272D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516275D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516270D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516274D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516269D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
RU2752528C2
(ru)
|
2016-01-06 |
2021-07-29 |
Хэлф Ресерч, Инк. |
Композиции и библиотеки, содержащие рекомбинантные полинуклеотиды, кодирующие Т-клеточные рецепторы, и способы применения рекомбинантных Т-клеточных рецепторов
|
CN117679499A
(zh)
|
2016-01-10 |
2024-03-12 |
尼奥克斯医疗有限公司 |
用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
|
US20190161530A1
(en)
*
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
AU2017261380A1
(en)
|
2016-05-06 |
2018-11-22 |
Editas Medicine, Inc. |
Genetically engineered cells and methods of making the same
|
JP2019517499A
(ja)
|
2016-06-02 |
2019-06-24 |
イムノコア リミテッド |
gp100特異的TCR−抗CD3 scFv融合タンパク質の投薬レジメン
|
EP3469362A1
(en)
|
2016-06-10 |
2019-04-17 |
Gadeta B.V. |
Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
|
CA3028002A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
WO2018071873A2
(en)
|
2016-10-13 |
2018-04-19 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
EP3534940A1
(en)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
JP2019532997A
(ja)
|
2016-11-03 |
2019-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法とbtk阻害剤との併用療法
|
EP3548083A1
(en)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
EP3548046A2
(en)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
|
MA46963A
(fr)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics Inc |
Méthodes pour déterminer le dosage de céllules car-t
|
CA3045338A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
WO2018132518A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
CN110418802A
(zh)
|
2017-01-20 |
2019-11-05 |
朱诺治疗学有限公司 |
细胞表面缀合物及相关的细胞组合物和方法
|
IL267990B2
(en)
|
2017-01-25 |
2024-04-01 |
Molecular Templates Inc |
Cell-targeted molecules containing Shiga toxin A subunit activators and nonimmune CD8 T-cell epitopes
|
CN110612119A
(zh)
*
|
2017-02-07 |
2019-12-24 |
西雅图儿童医院(Dba西雅图儿童研究所) |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
CN110461335A
(zh)
|
2017-02-17 |
2019-11-15 |
弗雷德哈钦森癌症研究中心 |
用于治疗bcma相关癌症和自身免疫性失调的联合疗法
|
US20200191774A1
(en)
|
2017-02-27 |
2020-06-18 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための組成物および方法
|
AU2018234640B2
(en)
|
2017-03-14 |
2024-03-14 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
MX2019012189A
(es)
|
2017-04-14 |
2020-12-10 |
Juno Therapeutics Inc |
Metodos para valorar la glucosilacion de la superficie celular.
|
FI3618842T3
(fi)
|
2017-05-01 |
2023-12-15 |
Juno Therapeutics Inc |
Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä
|
CN107216371B
(zh)
*
|
2017-05-27 |
2020-09-18 |
浙江师范大学 |
一种成人t细胞白血病的特异性靶向多肽及其应用
|
JP7379164B2
(ja)
|
2017-06-02 |
2023-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法に関連する毒性に関する製造物品および方法
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
US20220225597A1
(en)
|
2017-06-29 |
2022-07-21 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
WO2019027850A1
(en)
|
2017-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS
|
JP7275104B2
(ja)
|
2017-08-09 |
2023-05-17 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞の組成物および関連組成物を産生するための方法
|
US20200239910A1
(en)
|
2017-08-09 |
2020-07-30 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
WO2019051335A1
(en)
|
2017-09-07 |
2019-03-14 |
Juno Therapeutics, Inc. |
METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
HPV-SPECIFIC BINDING MOLECULES
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
US20210254000A1
(en)
|
2017-11-01 |
2021-08-19 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
BR112020008340A2
(pt)
|
2017-11-01 |
2020-11-17 |
Juno Therapeutics Inc |
processo para gerar composições terapêuticas de células modificadas
|
EP3706754A1
(en)
|
2017-11-06 |
2020-09-16 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
US20230137729A1
(en)
|
2017-11-06 |
2023-05-04 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
GB201719169D0
(en)
|
2017-11-20 |
2018-01-03 |
Univ College Cardiff Consultants Ltd |
Novel T-cell receptor and ligand
|
EP3716980A1
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
US20210207080A1
(en)
|
2017-12-08 |
2021-07-08 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
WO2019113559A2
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
SG11202005272SA
(en)
|
2017-12-08 |
2020-07-29 |
Juno Therapeutics Inc |
Process for producing a composition of engineered t cells
|
JP2021512147A
(ja)
|
2018-01-22 |
2021-05-13 |
エンドサイト・インコーポレイテッドEndocyte, Inc. |
Car t細胞の使用方法
|
JP7181517B2
(ja)
*
|
2018-01-23 |
2022-12-01 |
国立大学法人三重大学 |
T細胞レセプター
|
EP3746117A1
(en)
|
2018-01-31 |
2020-12-09 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
SG11202009446TA
(en)
|
2018-04-05 |
2020-10-29 |
Juno Therapeutics Inc |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
US11471489B2
(en)
|
2018-04-05 |
2022-10-18 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
MA52656A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
|
US20220275043A1
(en)
*
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
KR20210057730A
(ko)
|
2018-08-09 |
2021-05-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
조작 세포 및 이의 조성물 생성 방법
|
EA202190469A1
(ru)
|
2018-08-09 |
2021-06-28 |
Джуно Терапьютикс, Инк. |
Способы оценки интегрированных нуклеиновых кислот
|
BR112021004261A2
(pt)
|
2018-09-11 |
2021-05-25 |
Juno Therapeutics Inc |
métodos para análise por espectrometria de massas de composições de células geneticamente modificadas
|
US20210380661A1
(en)
*
|
2018-10-16 |
2021-12-09 |
Texas Tech University System |
Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
|
CA3117539A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
EP3873919A1
(en)
*
|
2018-11-02 |
2021-09-08 |
University of Washington |
Orthogonal protein heterodimers
|
JP2022512913A
(ja)
|
2018-11-06 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作されたt細胞を作製するための方法
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
KR20210117260A
(ko)
|
2018-11-30 |
2021-09-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료방법
|
MX2021006244A
(es)
|
2018-11-30 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
WO2020230142A1
(en)
|
2019-05-15 |
2020-11-19 |
Neotx Therapeutics Ltd. |
Cancer treatment
|
CA3139965A1
(en)
|
2019-06-07 |
2020-12-10 |
Ivie AIFUWA |
Automated t cell culture
|
KR20220034782A
(ko)
|
2019-06-12 |
2022-03-18 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 매개 세포 독성 요법 및 친생존 bcl2 패밀리 단백질 억제제의 병용 요법
|
EP4017527A1
(en)
|
2019-08-22 |
2022-06-29 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
|
AU2020377043A1
(en)
|
2019-10-30 |
2022-06-02 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
EP4070097A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
|
IL294988A
(en)
|
2020-01-24 |
2022-09-01 |
Regeneron Pharma |
Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 형질도입 방법
|
US20230085724A1
(en)
|
2020-03-05 |
2023-03-23 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
US20210403528A1
(en)
*
|
2020-05-21 |
2021-12-30 |
University College Cardiff Consultants Ltd. |
Novel T-Cell Receptor and Ligand
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
WO2022060904A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
|
JP2023548045A
(ja)
|
2020-10-23 |
2023-11-15 |
アッシャー バイオセラピューティクス, インコーポレイテッド |
免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
AU2022241654A1
(en)
|
2021-03-22 |
2023-09-28 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
BR112023019847A2
(pt)
|
2021-03-29 |
2023-11-07 |
Juno Therapeutics Inc |
Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
WO2023283446A1
(en)
*
|
2021-07-09 |
2023-01-12 |
The Johns Hopkins University |
Method for surface expression of membrane proteins that have a cytoplasmic c-terminal tail
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
US20240148867A1
(en)
|
2022-10-31 |
2024-05-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|